Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. Jongsma MME, et al. Among authors: van pieterson m. Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Jongsma MME, Vuijk SA, Cozijnsen MA, van Pieterson M, Norbruis OF, Groeneweg M, Wolters VM, van Wering HM, Hojsak I, Kolho KL, van Wijk MP, Teklenburg-Roord STA, de Meij TGJ, Escher JC, de Ridder L. Jongsma MME, et al. Among authors: van pieterson m. Eur J Pediatr. 2022 Aug;181(8):3055-3065. doi: 10.1007/s00431-022-04496-7. Epub 2022 Jun 8. Eur J Pediatr. 2022. PMID: 35672586 Free PMC article.
Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
Jongsma MME, Costes LMM, Tindemans I, Cozijnsen MA, Raatgreep RHC, van Pieterson M, Li Y, Escher JC, de Ridder L, Samsom JN. Jongsma MME, et al. Among authors: van pieterson m. J Crohns Colitis. 2023 Aug 21;17(8):1262-1277. doi: 10.1093/ecco-jcc/jjad049. J Crohns Colitis. 2023. PMID: 36934327 Free PMC article. Clinical Trial.
Effectiveness of transitional care in Inflammatory Bowel Disease; Development, Validation, and Initial outcomes of a Transition Success Score.
van Gaalen MA, van Pieterson M, Waaijenberg P, Kindermann A, Wolters VM, Dijkstra A, van Wering H, Wessels M, de Ridder L, Rizopoulos D, Derikx CLA, Escher JC. van Gaalen MA, et al. Among authors: van pieterson m. J Crohns Colitis. 2024 Nov 2:jjae166. doi: 10.1093/ecco-jcc/jjae166. Online ahead of print. J Crohns Colitis. 2024. PMID: 39487645
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, Norbruis OF, Groeneweg M, Wolters VM, van Wering H, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg S, Rizopoulos D, Poley MJ, Escher JC, de Ridder L. Vuijk SA, et al. Among authors: van pieterson m. Aliment Pharmacol Ther. 2024 Jun;59(12):1510-1520. doi: 10.1111/apt.18000. Epub 2024 Apr 21. Aliment Pharmacol Ther. 2024. PMID: 38644588 Clinical Trial.